Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 6/20 | 0.60 |
| ▸ | CTSL | P07711 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159283 | 1.00 | CTSV (0.60) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL16053347 | 0.94 | CTSV (0.56) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL8316504 | 0.94 | CTSV (0.61) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL38657998 | 0.93 | LMNA (0.64) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL31151917 | 0.92 | CTSV (0.53) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL340310 | 0.91 | MEN1 (0.56) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL13936617 | 0.91 | MEN1 (0.56) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL1013111 | 0.90 | MEN1 (0.57) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL3420694 | 0.90 | LMNA (0.55) | CTSVCTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL2063806 | 0.90 | MEN1 (0.57) | CTSVCTSLMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1696914-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058318-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-30 | — | — | WO | disclosed |
| US-6800644-B2 | PHOSPHODIESTERASE-4 INHIBITOR, AMINOQUINOLINE OR AMINOISOQUINOLINE DERIVATIVES | EISAI CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20020055516-A1 | Nitrogen-containing heterocyclic compounds and medicaments containing the compounds | EISAI CO., LTD. | 2002-05-09 | — | — | US | disclosed |
| US-6352989-B1 | ENZYME INHIBITORS FOR PHOSPHODIESTERASE | EISAI CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-1052254-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055516-A1 | Nitrogen-containing heterocyclic compounds and medicaments containing the compounds | PDE4A, PDE4B, PDE5A | CTSV 2609/4885CTSL 1963/4885MEN1 1229/4885 |
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | CBR3, CBR1, CYCS | CTSV 2732/4885CTSL 2075/4885MEN1 3326/4885 |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CTSV 1636/4885CTSL 1752/4885MEN1 385/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CTSV 1636/4885CTSL 1752/4885MEN1 385/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CTSV 1636/4885CTSL 1752/4885MEN1 385/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | CTSV 1636/4885CTSL 1752/4885MEN1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.